Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Commentary|Articles|April 24, 2025
Oncology Experts Preview Top Abstracts From AUA 2025
Author(s)Caroline Seymour
Fact checked by: Chris Ryan
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
Advertisement
Advertisement
Ahead of the
Related to this article
Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.
Adding durvalumab to BCG induction and maintenance reduced high-risk recurrences in patients with papillary-only bladder tumors in POTOMAC.
Perioperative enfortumab vedotin plus pembrolizumab showed no clinically meaningful HRQOL detriment in cisplatin-eligible MIBC.
An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.
The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.
Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.
Advertisement
Advertisement